Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Karyopharm Therapeutics Inc. is a U.S.-based biopharmaceutical company focused on the discovery, development, and commercialization of novel cancer therapies targeting nuclear export mechanisms. The company operates within the oncology and biopharmaceutical industries, with its core scientific focus on selective inhibition of nuclear export (SINE). Karyopharm’s primary revenue driver is its approved oncology product, XPOVIO® (selinexor), which is used in the treatment of certain hematologic malignancies.
The company primarily serves oncologists, hospitals, and specialty cancer treatment centers, with a concentration on patients suffering from multiple myeloma and diffuse large B-cell lymphoma. Karyopharm’s strategic advantage lies in its proprietary SINE technology platform, which targets exportin 1 (XPO1), a validated oncogenic protein involved in cancer cell survival. Founded in 2008, Karyopharm evolved from a research-driven startup into a commercial-stage biotechnology company following the U.S. Food and Drug Administration approvals of selinexor beginning in 2019.
Business Operations
Karyopharm operates through a single reportable segment focused on oncology drug development and commercialization, with XPOVIO® (selinexor) representing its principal commercial product. Revenue is generated primarily from product sales in the United States and through collaboration and licensing agreements internationally. The company also continues to invest significantly in clinical research and development to expand selinexor into additional indications and to advance next-generation SINE compounds.
The company controls a proprietary drug discovery platform and associated intellectual property related to nuclear export inhibition. International operations are supported through strategic partnerships, most notably with Menarini Group for commercialization in Europe and other ex-U.S. territories. Karyopharm does not operate manufacturing facilities at scale and relies on third-party contract manufacturers for clinical and commercial supply.
Strategic Position & Investments
Karyopharm’s strategic direction centers on maximizing the lifecycle and commercial potential of selinexor while advancing earlier-stage oncology candidates. Growth initiatives include expanding approved indications, pursuing combination therapy regimens, and optimizing dosing strategies to improve tolerability and outcomes. The company has also invested in next-generation nuclear export inhibitors, such as eltanexor, though development priorities have shifted over time based on clinical data and capital allocation decisions.
Major investments have primarily taken the form of internal R&D spending rather than large-scale acquisitions. Karyopharm’s most notable strategic partnership is its licensing agreement with Menarini Group, which includes upfront payments, milestones, and royalties tied to international sales. The company’s pipeline remains focused on hematologic malignancies and solid tumors, with ongoing evaluation of emerging oncology applications for nuclear export inhibition.
Geographic Footprint
Karyopharm is headquartered in Newton, Massachusetts, and its primary commercial operations are concentrated in the United States. The U.S. market represents the majority of the company’s revenue due to direct sales of XPOVIO® and established relationships with oncology treatment centers.
Internationally, Karyopharm has a market presence across Europe, Asia, and other regions through licensing and distribution partnerships rather than direct operations. The collaboration with Menarini Group provides commercial reach in the European Union, while additional partners support access in Japan, China, and other global markets. Overall, Karyopharm’s international influence is driven by strategic alliances rather than owned infrastructure.
Leadership & Governance
Karyopharm was founded by scientists and entrepreneurs with expertise in nuclear transport biology and drug development. The leadership team emphasizes a science-driven, patient-focused strategy aimed at translating novel biology into clinically meaningful therapies. Governance is overseen by an independent board of directors with experience in biotechnology, pharmaceuticals, and corporate finance.
Key executives include:
- Richard S. Paulson – President and Chief Executive Officer
- Michael Kauffman, MD, PhD – Chief Medical Officer
- Aaron Graichen – Chief Financial Officer
- Sharon Shacham, PhD – Founder and former Chief Scientific Officer
- John H. Pitts – Chief Operating Officer
The leadership philosophy centers on disciplined capital management, regulatory execution, and leveraging differentiated science to address unmet needs in oncology.